Updates

These updates includes material published by third parties and compiled by PAHO. PAHO has taken reasonable precautions to verify the information contained in the document. However, this material is being distributed without warranty of any kind. The reader is responsible for the interpretation and use of this information and in no event shall PAHO be held liable for any damages arising from its use.
  • Updates
  • Official reports from pharmacovigilance programs
  • Clarifications/conclusions of events presented in previous communications
  • Other related updates
03/31/2021

New vaccine developments (30-03-2021)

Canada-based Medicago is developing the CoVLP (Coronavirus-Like-Particle) vaccine, the efficacy of which is still unknown.

Read more
03/30/2021

Vaccination and patients with long-term symptoms

There are a number of patients with COVID-19 who develop long-term symptoms after infection with SARS-CoV-2, for which the term "Long COVID" has begun to be used. The symptoms vary, but the most common are fatigue, shortness of breath, myalgia, and insomnia.

Read more
03/30/2021

ANVISA and Butantan discuss anti-SARS-CoV-2 equine serum tests

Technicians from the National Health Surveillance Agency (ANVISA) and the Butantan Institute in Brasil met to consider the requested authorization to research the use, in humans, of equine serum developed to combat COVID- 19, also known as anti-SARS-CoV-2 hyperimmune serum.

Read more
03/30/2021

Influenza-like illness after administration of COVID-19 vaccines

The Global Advisory Committee on Vaccine Safety (GACVS) of the World Health Organization (WHO) reviewed clinical trial data and a summary of reports of influenza-like illnesses following COVID-19 vaccination, drawn from the WHO Global Database of Individual Case Safety Reports (VigiBase).

Read more
03/23/2021

New vaccines development

The emergence of variants with the ability to evade the immune system is driving a search for new development strategies and expanding the range of viral epitopes, which the new vaccines are designed to address.

Read more